National Pharmaceuticals Corp. in Association With Globe Labs to Enter Into Discussion on Clinical Trials Protocols for GLB333
Friday March 18, 2011, 8:05 am EDT
MIAMI, FLORIDA--(Marketwire - 03/18/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" announced today that in conjunction with Globe Laboratories have identified a contract research organization (CRO) from Europe to develop protocols for clinical trials of GLB333. Parties have decided that the Clinical Investigations group from Vienna, Austria would be most suitable for conducting the Phase I clinical trials. The trials which would be the first for GLB333 shall focus on the ability of the drug to speed up wound healing in diabetes patients suffering from chronic wound and tissue efflux.
"We are pleased to have this critical step initiated to identify and potentially engage a strong and experienced CRO group to advise us and conduct the necessary work with our drug for proof of efficacy and performance", said Elaine Affleck, President of National Pharmaceuticals Corp.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM